The Onchocerca volvulus cysteine proteinase inhibitor, Ov-CPI-2, is a target of protective antibody response that increases with age.
Despite considerable efforts, a suitable vaccine against Onchocerca volvulus infection has remained elusive. Herein, we report on the use of molecular tools to identify and characterize O. volvulus antigens that are possibly associated with the development of concomitant immunity in onchocerciasis.T...
Saved in:
Main Authors: | Fidelis Cho-Ngwa (Author), Jing Liu (Author), Sara Lustigman (Author) |
---|---|
Format: | Book |
Published: |
Public Library of Science (PLoS),
2010-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Antibody responses against the vaccine antigens Ov-103 and Ov-RAL-2 are associated with protective immunity to Onchocerca volvulus infection in both mice and humans.
by: Parakkal Jovvian George, et al.
Published: (2019) -
The Immunomodulatory Role of Adjuvants in Vaccines Formulated with the Recombinant Antigens Ov-103 and Ov-RAL-2 against Onchocerca volvulus in Mice.
by: Jessica A Hess, et al.
Published: (2016) -
Identification and characterization of the Onchocerca volvulus Excretory Secretory Product Ov28CRP, a putative GM2 activator protein.
by: Ferdinand Ngale Njume, et al.
Published: (2019) -
Ivermectin resistance in Onchocerca volvulus: toward a genetic basis.
by: Sara Lustigman, et al.
Published: (2007) -
Development of Onchocerca volvulus in humanized NSG mice and detection of parasite biomarkers in urine and serum.
by: John B Patton, et al.
Published: (2018)